Literature DB >> 20601445

Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.

Windy Berkofsky-Fessler1, Monica Buzzai, Marianne K-H Kim, Steven Fruchtman, Vesna Najfeld, Dong-Joon Min, Fabricio F Costa, Jared M Bischof, Marcelo B Soares, Melanie Jane McConnell, Weijia Zhang, Ross Levine, D Gary Gilliland, Raffaele Calogero, Jonathan D Licht.   

Abstract

PURPOSE: To understand the changes in gene expression in polycythemia vera (PV) progenitor cells and their relationship to JAK2V617F. EXPERIMENTAL
DESIGN: Messenger RNA isolated from CD34(+) cells from nine PV patients and normal controls was profiled using Affymetrix arrays. Gene expression change mediated by JAK2V617F was determined by profiling CD34(+) cells transduced with the kinase and by analysis of leukemia cell lines harboring JAK2V617F, treated with an inhibitor.
RESULTS: A PV expression signature was enriched for genes involved in hematopoietic development, inflammatory responses, and cell proliferation. By quantitative reverse transcription-PCR, 23 genes were consistently deregulated in all patient samples. Several of these genes such as WT1 and KLF4 were regulated by JAK2, whereas others such as NFIB and EVI1 seemed to be deregulated in PV by a JAK2-independent mechanism. Using cell line models and comparing gene expression profiles of cell lines and PV CD34(+) PV specimens, we have identified panels of 14 JAK2-dependent genes and 12 JAK2-independent genes. These two 14- and 12-gene sets could separate not only PV from normal CD34(+) specimens, but also other MPN such as essential thrombocytosis and primary myelofibrosis from their normal counterparts.
CONCLUSIONS: A subset of the aberrant gene expression in PV progenitor cells can be attributed to the action of the mutant kinase, but there remain a significant number of genes characteristic of the disease but deregulated by as yet unknown mechanisms. Genes deregulated in PV as a result of the action of JAK2V617F or independent of the kinase may represent other targets for therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601445      PMCID: PMC2947624          DOI: 10.1158/1078-0432.CCR-10-1092

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  58 in total

1.  Role of the WT1 tumor suppressor in murine hematopoiesis.

Authors:  Julia A Alberta; Gregory M Springett; Helen Rayburn; Thomas A Natoli; Janet Loring; Jordan A Kreidberg; David Housman
Journal:  Blood       Date:  2002-12-05       Impact factor: 22.113

2.  Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia.

Authors:  L Catani; R Zini; D Sollazzo; E Ottaviani; A M Vannucchi; S Ferrari; M Baccarani; N Vianelli; R M Lemoli; R Manfredini
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

Review 3.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

4.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

5.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

6.  An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation.

Authors:  D M Loeb; J L Summers; E A Burwell; D Korz; A D Friedman; S Sukumar
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

7.  Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera.

Authors:  Sylvie Hermouet; Anne Godard; Danielle Pineau; Isabelle Corre; Sylvie Raher; Eric Lippert; Yannick Jacques
Journal:  Cytokine       Date:  2002-11-24       Impact factor: 3.861

Review 8.  Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling.

Authors:  Sofie Singbrant Söderberg; Göran Karlsson; Stefan Karlsson
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

9.  Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.

Authors:  Norihiko Kawamata; Seishi Ogawa; Go Yamamoto; Soren Lehmann; Ross L Levine; Yana Pikman; Yasuhito Nannya; Masashi Sanada; Carl W Miller; D Gary Gilliland; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2008-08-23       Impact factor: 3.084

10.  Identification of human thioredoxin as a novel IFN-gamma-induced factor: mechanism of induction and its role in cytokine production.

Authors:  Seol-Hee Kim; Jiyoung Oh; Ja-Young Choi; Ji-Young Jang; Myoung-Wha Kang; Choong-Eun Lee
Journal:  BMC Immunol       Date:  2008-11-05       Impact factor: 3.615

View more
  17 in total

1.  Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors.

Authors:  Swarna Mehrotra; Bhumika Sharma; Sonali Joshi; Barbara Kroczynska; Beata Majchrzak; Brady L Stein; Brandon McMahon; Jessica K Altman; Jonathan D Licht; Darren P Baker; Elizabeth A Eklund; Amittha Wickrema; Amit Verma; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2013-06-28       Impact factor: 5.157

2.  Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.

Authors:  Baobing Zhao; Yang Mei; Lan Cao; Jingxin Zhang; Ronen Sumagin; Jing Yang; Juehua Gao; Matthew J Schipma; Yanfeng Wang; Chelsea Thorsheim; Liang Zhao; Timothy Stalker; Brady Stein; Qiang Jeremy Wen; John D Crispino; Charles S Abrams; Peng Ji
Journal:  J Clin Invest       Date:  2017-11-20       Impact factor: 14.808

3.  Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.

Authors:  Brady L Stein; Donna M Williams; Ophelia Rogers; Mary Ann Isaacs; Jerry L Spivak; Alison R Moliterno
Journal:  Exp Hematol       Date:  2010-10-01       Impact factor: 3.084

4.  Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.

Authors:  Sangeeta Nischal; Sanchari Bhattacharyya; Maximilian Christopeit; Yiting Yu; Li Zhou; Tushar D Bhagat; Davendra Sohal; Britta Will; Yongkai Mo; Masako Suzuki; Animesh Pardanani; Michael McDevitt; Jaroslaw P Maciejewski; Ari M Melnick; John M Greally; Ulrich Steidl; Alison Moliterno; Amit Verma
Journal:  Cancer Res       Date:  2012-10-11       Impact factor: 12.701

5.  CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling.

Authors:  Katrin Faber; Lars Bullinger; Christine Ragu; Angela Garding; Daniel Mertens; Christina Miller; Daniela Martin; Daniel Walcher; Konstanze Döhner; Hartmut Döhner; Rainer Claus; Christoph Plass; Stephen M Sykes; Steven W Lane; Claudia Scholl; Stefan Fröhling
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

6.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Authors:  Raajit Rampal; Fatima Al-Shahrour; Omar Abdel-Wahab; Jay P Patel; Jean-Philippe Brunel; Craig H Mermel; Adam J Bass; Jennifer Pretz; Jihae Ahn; Todd Hricik; Outi Kilpivaara; Martha Wadleigh; Lambert Busque; D Gary Gilliland; Todd R Golub; Benjamin L Ebert; Ross L Levine
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

7.  Two clinical phenotypes in polycythemia vera.

Authors:  Jerry L Spivak; Michael Considine; Donna M Williams; Conover C Talbot; Ophelia Rogers; Alison R Moliterno; Chunfa Jie; Michael F Ochs
Journal:  N Engl J Med       Date:  2014-08-28       Impact factor: 91.245

8.  MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients.

Authors:  Huichun Zhan; Christopher Cardozo; Wayne Yu; Antai Wang; Alison R Moliterno; Chi V Dang; Jerry L Spivak
Journal:  Blood Cells Mol Dis       Date:  2012-12-21       Impact factor: 3.039

9.  Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

Authors:  Edwin Chen; Philip A Beer; Anna L Godfrey; Christina A Ortmann; Juan Li; Ana P Costa-Pereira; Catherine E Ingle; Emmanouil T Dermitzakis; Peter J Campbell; Anthony R Green
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

10.  Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.

Authors:  K L Rice; X Lin; K Wolniak; B L Ebert; W Berkofsky-Fessler; M Buzzai; Y Sun; C Xi; P Elkin; R Levine; T Golub; D G Gilliland; J D Crispino; J D Licht; W Zhang
Journal:  Blood Cancer J       Date:  2011-11-11       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.